Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $210 million, exceeding the high end of the pre-announced range, with a year-over-year growth of approximately 4% when excluding the impact from UnitedHealthcare's decision on GeneSight [6][25] - For the full year 2025, revenue was $824.5 million, with adjusted EBITDA of $14.3 million and adjusted EPS of $0.04, reflecting strong operational performance [8][28] - Adjusted gross margin for the fourth quarter was 70%, with adjusted operating expenses decreasing by $7 million year-over-year due to disciplined cost management [8][27] Business Line Data and Key Metrics Changes - Oncology revenue for the fourth quarter was $84.7 million, growing 2% year-over-year, with MyRisk test volume growth of 14% in the affected market and 11% in the unaffected market [16][18] - Prolaris revenue growth accelerated to 16% year-over-year in the fourth quarter, driven by 12% volume growth [16][17] - Women's health revenue was $88.5 million, an increase of 2% year-over-year, with hereditary cancer testing in the unaffected market growing by 3% and volume growth of 11% [18][19] - GeneSight revenue was $36.6 million, with volume growth of 9% year-over-year, despite challenges from UnitedHealthcare's coverage policy change [22][24] Market Data and Key Metrics Changes - The company served over 55,000 healthcare providers and delivered over 1.5 million test reports in 2025, indicating strong market penetration [8] - The mental health business saw a record number of ordering clinicians, exceeding 38,000 in the fourth quarter [22] Company Strategy and Development Direction - The company is focusing on high-growth market segments and plans multiple product launches, including the expanded MyRisk panel and the AI-enhanced Prolaris test [5][10] - The strategy includes strengthening commercial capabilities and expanding the sales team, with an investment of over $35 million to enhance organizational efficiency and growth [15][61] - The company aims to maintain leadership in urinary cancer testing while expanding into other cancer testing applications [9][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving high single-digit to low double-digit growth rates in 2027 and beyond, supported by new product launches and recovery in the prenatal business [39][40] - The company is optimistic about the potential for continued momentum in hereditary cancer testing and prenatal testing, with expectations for recovery in 2026 [20][21] Other Important Information - The company plans to simplify its reporting structure to align with its strategic focus areas, including cancer care continuum, prenatal health, and mental health [31][32] - The company is preparing for the commercial launch of Precise MRD for breast cancer, with an alpha launch starting next week [11][14] Q&A Session Summary Question: Confidence in long-term growth rate - Management highlighted the drivers of growth for 2026, including product launches and improvements in commercial execution, expressing confidence in returning to high single-digit growth rates [37][39] Question: MRD launch strategy - Management indicated a selective approach for the MRD launch, focusing on user experience and operational efficiency before expanding volume [40][42] Question: Prenatal growth expectations - Management acknowledged a decline in prenatal volume in Q1 but anticipated recovery in Q2 and beyond, supported by a focused sales team and new product launches [45][81] Question: Prolaris momentum and dynamics - Management noted that improved engagement with KOLs and expansion of the sales team contributed to Prolaris growth, while also acknowledging potential favorable comparisons in Q4 [74][76] Question: Customer impact from order management issues - Management emphasized the importance of addressing order management issues and expressed confidence in restoring customer relationships and achieving growth moving forward [86][88]

Financial Data and Key Metrics Changes - The company reported revenue of $206 million for Q3 2025, a decrease of 4% year-over-year, but a 5% growth when excluding specific headwinds [4][24][26] - Adjusted gross margin was strong at 70.1%, with adjusted EBITDA reported at $10.3 million [6][28] - Test volumes increased by 3%, but average revenue per test decreased by 7% [23][24] Business Line Data and Key Metrics Changes - Oncology revenue was $81.8 million, a decline of 1% year-over-year, with myRisk test volume growth of 16% in the affected market and 11% in the unaffected market [15][19] - Women's health revenue increased by 3% to $85.2 million, with hereditary cancer testing showing a 4% revenue growth and 11% volume growth year-over-year [19][20] - GeneSight revenue was $38.7 million, with an 8% volume growth year-over-year, despite challenges from UnitedHealthcare's coverage policy change [21][22] Market Data and Key Metrics Changes - The hereditary cancer testing market is estimated to be close to $5 billion, with less than 50% penetration, indicating significant growth opportunities [55] - The company is experiencing positive momentum in prenatal testing, with expectations for continued growth following the introduction of the FirstGene test [20][21] Company Strategy and Development Direction - The company is focusing on the cancer care continuum to accelerate growth, leveraging the myRisk test and expanding its portfolio to include other cancer screening and diagnostic tests [7][8] - There is a commitment to grow prenatal health and mental health revenues at or above market growth, with a disciplined investment approach [8][12] - The company is enhancing its commercial capabilities and organizational design to improve customer experience and market share [11][12][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver accelerated profitable growth, emphasizing the importance of operational efficiency and strategic partnerships [9][10][11] - The company is optimistic about the upcoming launches of new products, including an updated myRisk test and the Prolaris prostate cancer test [10][11][18] Other Important Information - The company reaffirmed its full-year 2025 financial guidance, projecting revenue between $818 million and $828 million [30] - The organizational redesign aims to reduce management layers and improve efficiency, which is expected to support revenue growth while controlling operating expenses [29][30] Q&A Session Summary Question: What are the offsets in savings as you go into 2026? - Management reaffirmed a commitment to profitable growth, focusing on the cancer care continuum and reallocating investments to support growth while managing operating expenses [36][37] Question: Any share shift in the NIPT market? - Management acknowledged challenges in operational execution but indicated improvements are being made, with expectations for future growth driven by new products [40][41] Question: Can you provide color on the friction with the new ordering management system? - Management noted that regaining customer volume takes time, but improvements are being made, and they expect to show volume growth in the coming quarters [44][45] Question: What is the current average turnaround time for Prequel results? - Management stated that turnaround times for their products are competitive, emphasizing patient convenience and workflow improvements [68][69] Question: How should we think about ASP assumptions for 2026? - Management highlighted that ASP was impacted by several factors, including changes in payer mix and the divestiture of the EndoPredict business, but they expect positive trends to continue [63][64]